AGP collaborates with Childlife Foundation on Children’s Day 2023

AGP Launched Peridots – A Thanda Solution to Acidity, Gas and Indigestion

AGP secures 2nd Position at BCR Awards 2022

AGP wins Top Exporter Award at 6th PPMA Summit

AGP sponsors KDSP Carnival 2023

AGP bags big win at GDEIB Awards 2023

AGP continues partnership with IBA

AGP continues collaboration with TCF

AGP joins hands with SKMF

AGP continues partnership with ACF

AGP conducts Allergy Awareness Session At Pak Turk Maarif

Gong-Ringing Ceremony of AGP at PSX

Home > Products > TruGlif Met

Product List

TruGlif Met


Empagliflozin, Metformin HCl

Therapeutic Class:

SGLT2 Inhibitors & Biguanide Combs



  • TruGlif Met Tab 12.5 mg /500 mg: Each tablet contains 12.5 mg Empagliflozin and 500 mg Metformin HCl.
  • TruGlif Met Tab 12.5 mg /1000 mg: Each tablet contains 12.5 mg Empagliflozin and 1000 mg Metformin HCl.


TruGlif Met (Empagliflozin and metformin) is used with proper diet and exercise to treat high blood sugar levels caused by type 2 diabetes.



TruGlif Met is indicated for the treatment of adults with type 2 diabetes mellitus as an adjunct to diet and exercise:


• In patients insufficiently controlled on their maximally tolerated dose of metformin alone

• In combination with other medicinal products for the treatment of diabetes, in patients insufficiently controlled with metformin and these medicinal products

• In patients already being treated with the combination of empagliflozin and metformin as separate tablets.


The maximum recommended dose is 12.5 mg empagliflozin and 1000 mg metformin HCl twice daily. Take twice daily with meals, with gradual dose escalation to reduce the gastrointestinal side effects due to metformin.


  • Adults with normal renal function (GFR ≥90 ml/min)

The recommended dose is one tablet twice daily. The dosage should be individualized on the basis of the patient’s current regimen, effectiveness, and tolerability using the recommended daily dose of 10 mg or 25 mg of empagliflozin, while not exceeding the maximum recommended daily dose of metformin.


  • For patients switching from separate tablets of empagliflozin and metformin

Patients switching from separate tablets of empagliflozin and metformin should receive the same daily dose of empagliflozin and metformin already being taken or the nearest therapeutically appropriate dose of metformin.


  • Renal impairment

Not recommended in patients with an eGFR less than 45 mL/min/1.73 m2, due to the metformin component


  • TruGlif Met Tablets 12.5 mg / 500 mg available in pack of 14’s.
  • TruGlif Met Tablets 12.5 mg /1000 mg available in pack of 14’s.